Source comparison
Healing & Recovery Peptides: Research Applications Comparison
BPC-157 VEGF upregulation, nitric oxide modulation, fibroblast activation Tendon/ligament injury, gastric ulceration, inflammatory bowel models Subcutaneous injection, intraperitoneal (rodent models), oral (limited studies) 10–20 mcg/kg daily for 14–28 days in
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, nitric oxide modulation, fibroblast activation
- Tendon/ligament injury, gastric ulceration, inflammatory bowel models
- Subcutaneous injection, intraperitoneal (rodent models), oral (limited studies)
- 10–20 mcg/kg daily for 14–28 days in rodent models
- Strong preclinical evidence in soft tissue repair; oral bioavailability debated; requires temperature-controlled storage
- TB-500 (Thymosin Beta-4)
- Actin binding, cell migration, anti-inflammatory cytokine modulation
- Dermal wounds, corneal injury, vascular injury, myocardial infarction models
- Subcutaneous or intramuscular injection
- 2–10 mg twice weekly in mammalian models
- Broad tissue repair applications; well-documented in wound healing; longer half-life than BPC-157
- GHK-Cu
- Copper chelation, collagen cross-linking, metalloproteinase activation
- Dermal aging, wound healing, hair follicle stimulation
- Topical application, subcutaneous injection
- 1–3 mg/mL topical formulations; 0.5–2 mg subcutaneous 2–3× weekly
- Dermatological research standard; effective topically; plasma levels decline 80% from age 20 to 60
- IGF-1 LR3
- IGF receptor agonism, PI3K/Akt/mTOR pathway activation
- Muscle wasting, bone healing, metabolic research
- Subcutaneous injection
- 20–100 mcg daily in preclinical models
- Extended half-life vs endogenous IGF-1; potent anabolic signal; requires refrigeration post-reconstitution
- Ipamorelin
- Ghrelin receptor agonism, pulsatile GH release
- Growth hormone deficiency models, sarcopenia, bone density research
- 200–300 mcg 2–3× daily in human-equivalent dosing
- Selective GH secretagogue; minimal cortisol/prolactin elevation; short half-life requires multiple daily doses
- Sermorelin
- GHRH receptor agonism, endogenous GH stimulation
- Aging-related GH decline, body composition, sleep quality studies
- Subcutaneous injection before sleep
- 200–500 mcg nightly in human trials
- Mimics natural GH pulsatility; less suppression of endogenous GH than exogenous GH administration